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Abstract
Single or repetitive i.p. injections of Phytohemagglutinin (PHA) induced
a selective marked decrease in blood and bone marrow lymphocytes in mice,
suggesting that PHA might have a specific immunosuppressive effect.

To test

this hypothesis, parallel' experiments were conducted using female C57Bl/6J
(H-2b) mice as recipients and either female C3H/HeJ (H-2k) or female (C57Blx
C3He) Fl (H-2b,k) hybrid mice as donors of full-thickness skin grafts.
lmmunosuppression, as indicated by prolonged graft life, was induced by 4s
little as a single injection of 0.1 mg and increased with the dose to the
maximum tolerated dose of 3.0 mg PHA.
tested.

Several time and dose responses were

Maximal immunosuppression was induced using a regimen of 3.0 mg i.p.

24 hrs. before grafting, followed by daily injection of 0.5 mg PHA i.p.
These results lend support to the hypothesis that PHA, like anti-lymphocyte
serum, has a specific suppressive effect on cel1-mediated immunity.
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Introduction
Renaissance painters have depicted attempts to allograft human tissues
which occurred as early as the fourth century A.D.

Through the years, many

individuals have attempted grafts of heterogeneic (interspecies), allogeneic
intraspecies), syngeneic (among identical twins or members of inbred strains)
and autogeneic (within the same individual) materials with variable

~ucc~s.s.

Advances in the fields of immunology and surgery within the last 25 years,
however, have made it possible to transplant a full spectrum of organs and
tissues.
performed.

Allografts of bone, cartilage and blood vessels are now routinely
Grafts of this nature,however, are unique in that none of these

three types of tissue is substantially antigenic (10,19).

Sophisticated

surgical techniques allow even the replantation of severed limbs and digits
now with retention of at least partial function of the appendage (54).
Further, it is technically possible to experimentally transplant a diverse
spectrum of organs such as kidney, lung, liver, heart, pancreas, stomach and
various endocrine glands (5,17,20,49,55,59).

Clinically, though, only kidney

allografts are routinely performed.
Extensive work on the genetics of transplantation has shown that the
success of transplants is determined by multiple histocomatibility genes
designated by the letter H.

These H genes express

located primarily on cell surfaces, which incite

thems~lves

a~

as alloantigens,

immune response when

transferred into a host with antigenic specificities differing from those of
the donor animal.

In mice, analysis by linkage tests employing marker genes,

and analysis by transplants from parental strains to their PI-hybrid off ..
spring have shown that there are at least 15 H loci.

Further, these have
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been shown to be codominant, i.e., individually expressed in the heterozygote.
The loci are widely distributed throughout the

chro~somes

and the majority

of available evidence indicates that they are multiple allelic systems with
many possible antigenic specificities for each locus.

Histocompatibility

loci also exhibit varying immunogenicity or strength; most impose only weak
barriers to transplantation and are easily overcome or are not expressed
some genetic backgrounds.

on

The H-2 locus, an extremely complex system of

multiple alleles, presents the strongest transplantation barrier known in
mice, and is seldom overcome even by tumor transplants (23).

Familial studies

of antigen distribution indicate that the situation in humans is analogous
to that in mice (3,11), and definitive tests of histocompatibility have been
developed which allow close matching of donors to recipients.
Two factors remain the major obstacles preventing successful allografting of tissues and organs.

Procedures for obtaining and preserving donor

tissues for subsequent transplantation must first be improved.

To this end,

the use of cadaver donors seems to be the most promising; through the use of
organ perfusion with chilled Ringer's solutions and storage at low temperatures, the period of viability of many organs has been greatly extended and
the destructive effects of post-mortem anoxia and autolysis minimized.

These

techniques now allow the use of cadaver kidney for transplantation and are
being established for use with other organs (27).

The second factor is the

problem of inducing specific immune suppression of, the response to allogeneic
materials without producing undesirable side effects.

This difficulty in

inducing specific immunosuppression is a consequence of the complex mechanism

3

of graft rejection and of the diffuse nature of the lymphoid and reticuloendothelial systems.

According to Elves (12), the development of blood

vessels between the graft and host during rejection of allografts is followed
by migration of host mononuclear and neutrophil leucocytes into the graft.
These cells include a high proportion of small lymphocytes which become sensitized to the graft antigens probably by either of two means:

(a) direct'

interaction with soluble antigens that the graft has shed, or (b) indirectly
by means of an RNA-like transfer factor liberated by macrophages which have
ingested and processed antigenic graft materials.

These sensitized lympho-

cytes then either leave the graft via the afferent lymphatics to the regional
lymph nodes where they instigate a proliferative reaction resulting in the
production of first more sensitized lymphocytes and finally antibody-containing plasma cells, or they remain in the graft where at some stage in rejection they probably transform into large pyrononophilic cells which have the
ability to divide.

It is likely that following division, these cells become

mature plasma cells--this latter cell type appearing in large amounts when
the graft is already necrotic.

The small lymphocytes formed in the lymph

nodes are released into the lymphatics and circulation from which some return
to the graft and participate in the rejection reaction.

From

~

vitro

experiments, it appears that rejection is the result of direct cytocidal
action on the part of the small lymphocytes, which may also contribute to the
rejection by occluding the afferent blood supply to the graft.

The plasma

cells which appear in the lymph nodes and graft not only contain antibody to
the graft donor's antigens, ,but are probably synthesizing it.

This antibody

seems, however, to play only a minor role in the allograft response; titers
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very often rise only upon rejection of the graft, and such rises are unpredictable.

It is most likely that this antibody plays only an opsonic role

and in itself is not a sufficient cause for graft rejection.

Recently,

Rapaport et a1. (43,44) have reported that a110grafting is associated with
a marked rise in the level of circulating heterophile antibodies.

They

suggested on this basis that allograft rejection may be partly the result of
an immune response to heterophile antigens in the graft tissue.

This finding

has also opened new alleys of investigation on the problem of autoimmunity.
Further, lymphocytes and macrophages are widely distributed throughout the
tissues of the body, necessitating that a systemic rather than localized
treatment be used to achieve immunosuppression.
The agents currently in use for inducing immunosuppression leave much to
be desired because of their lack of specificity of suppression and the extent
of their side effects.

There are, according to Berenbaum (4) and Schwartz

(47), four means by which immunosuppressive agents can act:

enzyme inhibition

template damage, structural damage, and mitotic inhibition.

Accomplishment

of anyone or a combination of these effects leads to reduced, unbalanced,
or misdirected synthesis of cellular components and ultimately to cell death.
The agents currently preferred, such as azathioprine, prednisone, actinomycinC, and X-irradiation, accomplish their purpose primarily as a result of the
selectively greater sensitivity of the lymphoid syAtem compared to other
tissues rather than as a result of any specifically unique sensitivity of the
lymphoid system to these agents.

In addition, Starzyl (51) has shown that,

in kidney transplant patients, the patient with a rejection crisis and thus
in most need of effective immunosuppressive therapy is also the most suscept-
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ible to the induction of irreversible bone marrow failure leading to infection
and death.
Another possible approach to immunosuppression is chronic thoracic duct
drainage, a means of specifically eliminating or depleting the immunologically
competent cells (i.e., small lymphocytes) and thereby rendering the host
unreactive to allografts.

Among others, Woodruff (64) through animal experi-

ments and Tilner et ale (56) through human therapy have shown this approach
to be effective in delaying the onset of the allograft response.

A disturbing

note, however, is the observation that once rejection begins, it proceeds
with the same rapidity and severity as an unimpaired response.

This phenomeno

and the limited extension of graft life obtained has limited the value of
lymphocyte depletion as a primary means of specific immune suppression, but
its value as an adjunct to other means is indicated by its additive effect
on azathioprine"prednisone therapy in human renal allografting.
To date, the only promising and apparently specific agent is anti ..
lymphocyte serum (ALS).

Many investigators have experimentally demonstrated

the substantial suppressive effect of this agent on allograft immunity (22,
29).

On the other hand, considerable problems have been encountered in the

use of ALS.

Most conspicuous of these are the lack of a reliable test in

,
~

which correlates with

the ALS.

~~

effect and the problem of specificity of

A third problem is the side effects associated with protracted

administration of the antiserum.
have been extensively studied:

There are four in vitro tests of ALS which
(a) RBe agglutination, (b) lymphocyte agglu-

tination, (c) lymphocyte cytotoxicity (in presence of complement), and (d)
lymphocyte transformation (RNA and DNA synthesis).

As yet, none of these

.6

tests has been shown to reliably predict
of ALS (63).

the!a~

immunosuppressive effect

Antigens with which ALS reacts are not only found in lympho-

cytes but are present in cells widely distributed throughout the body.

It

has been shown that even mouse tail skin epidermal cells can be used to
elicit an active ALS.

Seega1 et a1. (48) have observed a Masugi-type nephriti

presumably due to rapid bind~ng of antibody to the glomeruli of the trans~
planted kidneys.

Thus, the administration of ALS to prolong the life of allo-

grafts can lead to their eventual destruction as a result of
to both graft tissue and lymphocytes.

a~tigens

common

Serum sickness and anaphylactic

reactions have complicated protracted administration of ALS and the eventual
immune response to the foreign proteins of heterologous antisera limit the
length of time for which they can be administered (30).

The purification and

use of anti-lymphocyte globulin (ALG) which is much less immunogenic than
whole serum, however, has to an extent reduced these problems (63).

Levey

and Medawar have summarized in 12 points our present state of knowledge
concerning anti-lymphocyte serum:
1)

ALS has the character of an antibody

2)

ALS does not act by enhancement

3)

The activity of ALS resides predominantly in the 7S fraction

4)

ALS is not directed against antigens peculiar to lymphoid cells

5)

Lymphoid cells are the effective targets'of ALS

6)

ALS does not act through lymphocytic depletion

7)

The state of unresponsiveness induced by ALS is not immunological
tolerance
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8)

The immunosuppressive action of ALS is not a by-product of some
more generalized organic damage

9)

The immunosuppressive effect of ALS outlives its own metabolic
lifetime

10)

The effect of ALS on lymphoid cells persists through at least
one cell division

11)

ALS is particularly effective in the homograft reaction

12)

ALS may act in the first instance on peripheral lymphocytes

The attention of many investigators, particularly in the past few years,
has been drawn to phytohemagglutinin (PHA) in the expectation that this compound may have a specific suppressive effect on the allograft response in a
manner similar to that of anti-lymphocyte serum.

An aqueous extract of the

leguminous plant Phaseo1us vulgaris, PHA and similarly obtained extracts
from other plants of this genus have been known to researchers since Ehrlich
used them in his studies of antigen-antibody interactions.
There are two forms of Difco PHA (PHA-P and PHA-M) and a BurroughsWellcome PHA which are available commercially.

Rigas and Osgood (45) first

described the extraction of PHA-M from the red kidney bean in 1955 and
reported it to be a mucoprotein containing approximately 50% carbohydrate.

,

Pharmacologic activity was associated with the protein and in 1964, Rigas
and Johnson (46) outlined the procedure for dissociating the protein moiety
from the bulk of the polysaccharide under acid conditions.

This preparation,

which they labelled PHA-P, has approximately 50 times the erythro-agglutinating activity of PHA-M.

It has been determined experimentally by this

investigator that this proportionality is also true with respect to the

8

induction of transformation of human lymphocytes
or i.p. LD50/48 hrs.

~

vitro and either the i.v.

PHA-P has been further shown to have a sedimentation

coefficient of 6.5S, a diffusion coefficient of 4.8 cm2 sec· l xlO- 7 ,
ular weight of 128,000 and an isoelectric point of pH 6.5.
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molec-

It is poor in

sulfur-containing amino acids and rich in aspartic acid plus asparagine,
serine, threonine and leucine; it has alanine as the only N-terminal amino'
acid; it has a carbohydrate
content of 3.4%.
r

It is suspected but has not

been definitely shown that this carbohydrate is covalently linked to the
protein moiety.

There are at least 23 varieties of Phaseolus vulgaris, all

of which yield hemagglutinins of somewhat similar activity upon aqueous
extraction.

Although the very great majority of work

~

!!!!2 and

~ ~

with both humans and animals has been carried out with the extract of the
red kidney bean, occasional reports have been published using the phytohemagglutinins from other varieties of Phaseolus vulgaris.

These prepara-

tions all exert somewhat similar agglutinating activities, but they differ
considerably in their toxicities and physical properties and may also differ
in their mitogenic activities (53).

Previous work from this laboratory has

further shown that PHA-P varies considerably in activity from lot to lot as
measured by the

~

vitro transformation of lymphocytes.

In 1929 Goddard and Mandel published work which involved possible
vivo toxic effects of PHA in rabbits (21).
remained only in its agglutinating

~

Interest in PHA, however,

pro~erties

as a tool in preparing cel1-

free sera until 1960 when Nowell reported the mitogenic effect of PHA on
peripheral blood leucocytes

~~

(40).

Since then, several investigators

have described the blastoid transformation of lymphocytes induced in vitro
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by this substance (8,34).

In addition, this blastoid transformation has

been shown to be preceeded by an exponential acceleration of RNA, protein,
and DNA synthesis.

Bach and Hirschhorn (1) have reported a rise in the gamma

globulin content of lymphocytic cells resulting from treatment
human lymphocytes with phytohemagglutinin.

~

vitro of

They suggested from this that

this morphologic transformation of lymphocytes arises as an immunologic ' ..
reaction to PHA acting as a non-specific antigen and stimulating antibody
production.

Similarly, Elves et ale (14) reported detectable amounts of

gamma globulin arising in transforming human small lymphocytes subsequent to
treatment

~

vitro with PHA or antigens.

Since then, however, other authors

have demonstrated that PHA stimulates all classes of RNA and protein and
DNA (32,36) suggesting that the lymphocytes' resfonse to PHA differs biochemically from their response to antigens.

It is interesting that, as mentioned

above, anti-lymphocyte serum has also been shown to induce blastoid transformation in peripheral blood lymphocytes

~

vitro even though this property

of ALS is not a requisite for immunosuppression in

~

(63).

Phytohemagglutinin has been used in patients with aplastic anemia in the
attempt to restore their bone marrow cellularity (16,26,60).

PHA has also

been used in the Veterans Administration Hospital, Hines, Illinois on two

•

patients with bronchogenic carcinoma treated by external irradiation (52).
Few experiments have been conducted on laboratory animals in the attempt of
proving the validity of the clinical treatment.

Elves et ale (15) failed

to demonstrate any consistent effects in rats after one or repetitive i.v.
or i.p. injections of PHA.

Papac (41) reported that mice and rats exposed

to varying doses of irradiation failed to show stimulation of marrow regener-
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ation after treatment with the highest tolerated. doses of PHA administered
i.v.
The possibility of an immunosuppressive effect of phytohemagglutinin has
been previously suggested by the work of CaIne and Wheeler (9).

In a pre-

liminary report, they observed following combined treatment with PHA and
azathioprine a moderate prolongation of the life of renal allografts.

These

authors noted a slight immunosuppressive activity of PHA alone and a potentiation of the effect of the Imuran.

In addition,

~o

recent papers, one by

Spreafico et a1. (50) and the second by Elves (13), have shown that phytohemagglutinin can suppress antibody synthesis

~~.

Following the i.v.

administration of this compound to rats, these authors noted a decrease in
the amount of hemolytic antibody formed during the primary and secondary
immune response to chicken or sheep red blood cells.
Using skin allograft rejection in mice as a marker of immune competence,
the present work was undertaken to answer the following three specific
questions:
1)

What is the effect of phytohemagglutinin on cell-mediated immunity
as measured by prolongation of the life of mouse skin allografts
following i.p. administration of PHA?

2)

What is the optimal dose and most effective schedule of administration of this preparation in prolonging mouse skin allograft life?

3)

What is the relationship of the

~

in vitro action of this compound?

!!!2

effects of PHA to the
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Material and Methods
Animals.

Adult female CFI mice eight to ten weeks of age (Carworth

Farms Inc.) were used for the blood and bone marrow studies.

It was felt

that a disparity across the H-2 locus would provide the most definitive test
of immunosuppression.

Accordingly, adult female C3H/HeJ (H-2b) mice eight

to ten weeks of age and adult femaleC57BL/6J (H-2k) mice of the same age-'
(Roscoe B. Jackson Memorial Laborator1es) were used for these experiments.
Also used in this study were eight to ten weeks old adult female (C3H x
C57) F1 (H-2b,k) hybrid mice bred from the above stocks.
Phytohemagglutinin.

Each vial containing 100 mg phytohemagglutinin-P

(PHA-P, Difco lot nos. 497992 and 496843) was diluted with 5.0 ml sterile
isotonic saline.

For the several doses of PHA used in this study, dilutions

were made with sterile isotonic saline to the desired amounts of PHA per
0.5 cc, the amount of fluid injected i.p.
Absolute and differential counts.
tail veins of mice.

Blood samples were taken from the

Smears were made, stained with Wright's stain, and 100

cells counted to establish a differential count.

According to standard

hematologic procedure (61), blood samples were diluted in a WBC serologic
pipette with a 3% solution of HCl and New Methylene Blue to hemolyze the RBC
and counted in a hemacytometer to determine the absolute WBC.

From these

two counts, the absolute number of lymphocytes was· calculated.

Blasts and

mitoses in the bone marrow were counted as part of the differential.
Skin grafting.

Adopted for this tudy was a modification of the method

described by Medawar using full-thickness skin grafts (33).

Twenty-four

hours before grafting, the donor animal and prospective recipients were
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closely shaved with an electric clippers, number 40 head.

Immediately prior

to grafting, the donor animal was sacrificed by cervical dislocation and
skinned using aseptic technique.

•

The skin was then stretched out inner side

up at even tension, flushed with sterile saline, scraped free of fat and
fascia with a sterile number 11 scalpel, and from 20 to 30 circular grafts
1.0 cm in diameter were cut using a sterile cork borer.

These grafts were

then placed between filter paper wet with sterile saline at 4

0

C until use.

While being held in the investigator's left hand, each recipient mouse was
lightly anesthetized using an ether nose cone, and a bloodless circular graft
bed to the level of the panniculus carnosus was prepared on the ventral chest
wall using a

s~a11,

sharply pointed, curved scissors.

First, make a nick at

the posterior end of the bed site with the point of the scissors.

Next,

reverse the scissors and free the skin from the underlying tissue by sliding
them through the nick and under the skin then spreading the points slightly.
Lastly, cut a circular piece of skin 1 em in diameter to expose the panniculus
o
carnosus. The graft was placed in position, rotated 180 from normal hair
direction, and the edges of the graft apposed evenly and symmetrically to the
edges of the bed.

No sutures were used; the graft was held in place by means

of an overlay of vaseline impregnated gauze and a dressing of adhesive tape.
The animals were housed two per cage for seven days postoperatively, at which
time the dressings were removed and a loose dressing of gauze and scotch tape
placed on the animal for 24 hours.

When this final dressing was removed,

the animals were housed five per cage and examined daily for evidence of
graft rejection.
Graft rejection.

Complete rejection of the graft was taken as the end
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point of each experiment.

in

grafts

~

This was determined by visual inspection of the

according to criteria established by Billingham et a1. (6).

Experimental procedure.

Each experiment was designed and carried out

as discussed in the results.

Each point on the charts of the experimental

.

graft groups represents 15 to 20 mice (average graft survival

± one

S.D.)

and there are 30 to 40 mice represented by the plots of control graft survival

± one

S.D.

limits.

All blood and bone marrow studies are shown with 95% confidence

Each experimental group contains at least 5 animals and the control

groups contain 10 to 15 animals.

No animals were bled more than one time.
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Results
The first experiment was designed to test the effect of a single 3.0 mg
dose of PHA as a function of time between administration of the PHA and grafting.

As can be seen in Figure I, PHA given from 30 minutes after to three

days before grafting induces in the C3H to C57 system a significantly longer
graft survival (10.4 days S.D.
(8.3 days S.D.

± 0.4).

± 1.0)

PHA had only

compared to the control graft survival

a small

effect on graft survival i f

given four days before grafting--the period of time shown in Figure 2 to
correspond with the time of lymphopenia induced in CFl mice by the same dose
of PHA.
Next, the effect of daily repetitive injections of 1.5 mg PHA i.p. was
tested.

Again, a better graft survival was noted in the PHA treated group

than in the control group, seen in Figure 3.

However, a slightly better

graft survival followed the single injection of PHA (10.5 days S.D. + 0.7)
rather than the repetitive injections, decreasing to a minimum value in the
four injection group (9.5 days S.D. + 0.8).
Several experiments were then performed to investigate the dose-dependence of skin graft life following a single injection of PHA i.p.

In these

experiments, both the C3H to C57 and the Fl-hybrid to C57systems were used.
Figure 4 shows that the average graft life was significantly prolonged in the
C3H system by treatment with PHA, but did not vary'significantly over the
dose range tested (10.3 days S.D.

± 0.5).

Even the small dose of 0.1 mg

-

significantly increased the graft survival '(10.2 days S.D. + 0.4) as compared
to the survival of control grafts '(8.3 days S.D.
was observed in the Fl-hybrid to C57 system.

±

0.4).

A different response

Here there was a direct correl-
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ation between dose and survival, higher doses affording longer survival.

No

correlation between graft survival time and peripheral blood lymphopenia was
observed in this experiment.

Table 1 relates the changes in absolute blood

lymphocyte levels to graft survival and dose of PHA used.

It is apparent

from this table that the immunosuppressive effect of PHA is not dependent
upon the production of peripheral blood lymphppenia.

A further observation

is that the relative percentage of blasts ·and mitoses in the bone marrow of
CFl mice following a single injection of 3.0 mg PHA i.p. (Fig. 5).rise concommitantly with the changes in the peripheral blood lymphocyte level.
Maximal prolongation of allograft survival has been obtained with the
following treatment.

First, one injection of 3.0 mg PHA was given intra-

peritoneally 24 hrs. before grafting.

The graft was followed by daily injec-

tions of 0.5 mg PHA starting one day postoperatively and extending from two
injections up to 14 injections in the C3H system or 24 injections in the
Fl-hybrid system, i.e., the time of complete rejection in the two systems.
Plotting graft survival against the number of daily injections, Figure 6
shows that there is again a disproportionate response in the C3H system with
respect to small doses of PHA while there is an approximately proportionate
response in the Fl-hybrid system.

In both systems, however, the maximum

graft life obtained is approximately 100% better than the control (14.0 days
S.D.

± 0.9

versus 8.3 days S.D. + 0.4 with C3H donors, and 23.9 days S.D.

1.2 versus 10.3 days S.D.

± 0.6

with F1-hybrid donors).

±

In all instances

the survival of grafts in the control group were significantly less than
those in the treated groups.
It is interesting that the degree and rapidity of rejection, once begun,
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Table 1.

COMPARISON OF GRAFT SURVIVAL AND ABSOLUTE
LYMPHOCYTE LEVELS AS A FUNCTION OF SINGLE
DOSE OF PHA-P I. P.
Dose PHA
mg. I. P.

Prolongation
Graft Life %
C3B
Fl

Absolute Blood Lymphocyte Count
cells/mm 3
2 days
4 days
7 days

5.6

9,500

14,500

4,500

22.3

12,200

15,850

10,900

1.0

21.7' 35.9

8,550

9,750

9,350

3.0

25.3

38.8

. 2,800

3,950

9,200

0.1

22.8

0.3

26.5

'.

6,600

No T.
._-_._ ..

__ ._----.- ..--

-
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was unaffected by the PHA treatment, and resembled the rejection process in
the control animals.

Further, in all experiments, no deaths could be attrib-

uted to the toxicity of PHA.

Extensive work with 12 week old female CFl mice

has shown that the LD50 at 48 hrs. for PHA-P injected intraperitoneally is
9.5 mg.

.

Due to the differences in weight between the CFl and C57BL strains,

this corresponds to an LD50 of 6.0 mg for the eight to ten week old CS7BL
mice used as graft recipients.
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Discussion
Extensive investigation of alternate methods of skin grafting found them
to be unsuitable for the purposes of this study before the procedure described
above was adopted.

This method is recommended by many considerations.

The

technique is quite simple and no sutures are needed to position the graft.
This results in practically eliminating the problem of infection due to experimental procedures.

Second, this technique is reliably and quickly performed;

less than 10% of the animals have to be discarded as a result of technical
error such as uncontrolled bleeding in the graft bed or movement of the graft
once it is in place.

Third, many grafts can be obtained from a siqgle animal,

thereby minimizing the possibility of antigenic variation being introduced
by large numbers of dpnor animals.

Fourth, there is no loss or alteration

of graft antigenicity for periods of time up to 6 hrs. as a result of the
methods used to prepare and store the skin grafts until use (62).

Fifth,

the uniform graft size insures both a more uniform antigenic challenge to the
recipient animal and a consequently more uniform immune response to the graft
antigens.

Galton (18) has shown that with grafts from F1-hybrids to either

parent or with grafts across non-H-2 loci, larger grafts have slightly shorter
survival times, indicating that in these systems, at least, the antigenic
dose to which the animal is exposed can be a significa~t variable.
In the above experiments, PHA-P injected intraperitoneally has been
shown to increase the survival of skin allografts in mice to a maximum value
of 71% in the e3H to e57 system and 132% in the Fl-hybrid to e57 system.
The maximum graft survivals obtained compare well with results obtained using
other current immunosuppressive agents.

Hoehn (27) using A to eBA (an H-2
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difference) grafts as his "strong" system and C3H to CBA (a non-H-2 difference
as his "weak" system obtained a 20% and 50% respective increase in graft
survival using paired Imuran and Actinomycin C therapy.

These results,

however, were
accompanied by a 60 to 70% mortality due to drug toxicity.
,
Treatment with bromodeoxyuridine and thioguanine in the "strong" system
resulted in a 60% increase in graft survival with a mortality of 13.3%.
animals which

succumbed~to

No

the effects of the therapy were included in the

calculation of graft survival.

Considerably better results were achieved by

Levey and Medawar (30) using anti-lymphocyte serum to prolong the life of
A strain skin grafts on CBA mice.

They reported a 134% prolongation of graft

life as compared to control graft survival with no apparent toxic effects due·
to the ALS.

Thus, it would seem that the results obtained with PHA compare

well with results achieved through other means of chemical suppression.

In

addition, PHA, like anti-lymphocyte serum, exerts its effects unaccompanied
by any apparent toxic side effects.
Initial studies of blood and bone marrow cell levels following treatment
with PHA suggested to us that the lymphopenia produced in both the peripheral
blood and bone marrow could lead to a delay in the allograft response.
During the course of this study, however, it became apparent that this phenomenon was inadequate to explain the longevity of allografts following treatments with PHA over the dose range and regimens .tested.

Although the length

of time during which prolonged graft life could be induced following a single
injection of PHA corresponded to the duration of peripheral blood lymphopenia,
grafts performed 30 minutes before or after injection of PHA also exhibited
a similarly prolonged survival.

This was interesting in that these grafts
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were performed before the period of lymphopenia became evident.

More reveal-

ing was the observation that graft life far outlasted the periods of lymphopenia in either the peripheral blood or bone marrow.

That lymphopenia pro-

duction is not the mode of action of PHA in suppressing allograft rejection
was conclusively established by the dose-response experiment in which it was
shown that doses of PHA which induced a pronounced lymphocytosis also 'induced
a marked prolongation of graft survival.

These results are further supported

by the observation that the relative number of blasts and mitoses in the bone
marrow rise following treatment with PHA.

What seems likely in the light of

these experiments is an explanation offered by Elves (13) who suggested that
"transformation of immunologically competent cells occurs in

.Y!Y2. with the

'siphoning off' of such cells so that they are not available to react ,,71th
the immunizing antigen", in this case the allograft.

The present study

supported this idea and suggested further insights into the. mechanism by which
the immunosuppression was induced by PHA.

From the studies of peripheral

blood and bone marrow following the administration of PHA, it appeared that
this compound acts on two distinct populations of lymphocytes in suppressing
allograft rejection.

The most important action of PHA is exerted primarily

on the central lymphocytes' through the transformation and subsequent "siphoning off" of immunocompetent cells.

.

This was evidenced by our

Own

observation

of the rise in the numbers of bone marrow blasts· and mitoses following injection of PHA and by Elves (15) who noted an increase in the mitotic activity
in the spleens of mice following injection of PHA.

A secondary action of

PHA, apparent only after higher doses, is the induction of lymphopenia in the
peripheral blood.

This effect seemed to result from either a direct cytocidal
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action of PHA or enhanced phagocytosis and clearance of circulating 1ymphocytes due to PHA-induced 1eukoagg1utination and was observed to make only'a
small addition to the prolongation of graft life accomplished by non-lymphopenia doses of PHA.
I

Many investigators have attempted to clarify the importance of and the
interrelationships between the three observed activities of phytohemagglutinin:
(a) erythroagglutination, (b)

leuko~gglutination,

blastoid transformation of lymphocytes.

and (c) stimulation of the

Barkhan et al. (2), using red

cel~

absorption, and Tunis (57), employing selective heat inactivation to eliminate
the red cell agglutinin, showed that this activity of PHA was not necessary
to the

~

vitro blastoid transformation of lymphoid cells.

Early attempts

at separating the white cell agglutinin from the lymphocyte mitogen failed,
however, and led to speculation that the b1astoid transformation induced by
PHA was merely the result of cell membrane changes following agglutination
(24,40).

As discussed in the introduction to this thesis, subsequent work

indicated that pHA may act as a non-specific antigenic challenge in inducing
blastoid transformation.
inadequate explanation.

More extensive work has shown this theory to be an
Recently, Weber et al. (58) using ion exchange

chromatography to separate the 1eukoagglutinating and lymphocyte-stimulating
activities of PHA, and Borjeson et a1. (7) using Vi polysaccharide to e1iminate the agglutination of leukocytes, have shown the leukocyte mitogen to
be physically distinct and independent of the leukocyte and erythrocyte
agglutinins.

A possible explanation of the basis for the mitogenicity of

PHA, although unsupported by direct experimental evidence, is that PHA may
act on a basic control mechanism of RNA synthesis leading to the eventual
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blastoid transformation of the lymphocyte.

Incidentally, this process may

be similar to the mechanism of antigenic induction of antibody synthesis as
suggested by a result of Spreafico and Lerner (50) who observed that PHA,
while transiently suppressing the primary and

second~ry

I

hemolysin response

to sheep RBC, enhanced the normal background reactivity of non-immunized mice
to this antigen.

The idea of PHA acting through a basic inductive

the metabolism of the cell is not new.

st~p

in

Mueller and LeMahieu (36) have sug-

gested that PHA may act primarily to counteract normal repressor mechanisms
regulating RNA synthesis.

Recently, Rabinowitz and Dietz (42) studying the

induction of lactate dehydrogenase (LDH) and malate dehydrogenase (MDH)
isozymes by PHA, concluded that "PHA acts at the two genetic loci controlling
synthesis of muscle and heart-type (M and H) lactate dehydrogenase polypep·
tide subunits".

They further stated that "the synthesis of the two isozymes

of malate dehydrogenase also may be under the control of separate genes which
in granulocytes are influenced by conditions of cell culture, rather than by
phytohemagglutinin".

Suggested as a means by which PHA accomplishes these

results was that it "may act at allosteric sites on protein repressors or inducers of operator genes for the M- and H-type polypeptides •••••••• ".

This

postulated mechanism of action of PHA is consistent with the view that this
compound parallels in many respects the action of hormones which act on many
sites on a variety of functionally different proteins.
In this thesis it has been shown that PHA-P given intraperitonea1ly is
effective in suppressing the rejection of allografts across the H-2 locus in
mice.

A regimen of one large dose of PHA prior to grafting followed by small

daily injections of this compound has been shown to yield results comparable

.

to those obtained with other immunosuppressive agents.
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Significantly, this

immunosuppression was not accompanied by any mortality or apparent toxic
effects of the PHA.

Studies of the blood and bone marrow suggest that the

suppressive\activity of PHA

~ ~

is not related to a lymphopenic effect

but is probably the result of the lymphocyte mitogen.

It thus appears that

PHA is comparable to anti-lymphocyte serum in its effectively specific
suppression of allograft rejection and its lack of toxicity in the treated
animal.

Comparing what is known of PHA to some of the points made by Levey

and Medawar (30) concerning anti-lymphocyte serum, it can be said that:
1)

Lymphoid cells are the effective targets of both PHA and ALS.

2)

Neither ALS nor PHA act through lymphocytic depletion.

3)

The states of unresponsiveness induced by either PHA or ALS are
not immunological tolerance.

4)

The immunosuppressive actions of PHA and ALS are not the by-products
of some more generalized organic damage.

5)

PHA, like ALS, is particularly effective in the homogra.ft reaction,
inducing only a transient suppression of the humoral immune
response (38,50).

6)

While ALS appears to act in the first instance on peripheral lymphocytes, experimental evidence indicates that PHA may act on the
central lymphoid orgons.

This last paint raises the interesting

speculation that combined PHA-ALS therapy may be particularly
effective and non-toxic in preventing allograft rejection in the
clinical situation.
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